

3/2023

EPTINEZUMAB-JJMR (VYEPTI) Infusion

NAME: **BIRTHDATE: INSURANCE:** PROVIDER NAME: **CLINIC NAME and Phone number:**

Patient identification

| Treat | me | ent Start Date: | | | |
|--------|------|--|--|--|--|
| **If t | rea | atment not started within 90 days, new orders with updated date/signature will be required. Otherwise, | | | |
| orde | rs a | are valid for 1 year from signature date.** | | | |
| GUID | ELI | INES FOR ORDERING | | | |
| 1 | L. | Patient <u>name and date of birth</u> must be on EACH page of this order form. This form will be returned if any | | | |
| | | left blank. | | | |
| 2 | 2. | Send FACE SHEET and complete copy of INSURANCE information. Send H&P or most recent chart note, | | | |
| | | must be within the past 12 months. | | | |
| 3 | 3. | Send a copy of related lab results if not available for review in Epic. | | | |
| Optio | ona | al LABS: | | | |
| Ţ | | CBC with differential, Routine, every | | | |
| Ţ | | CMP, Routine, every | | | |
| MED | ICA | ATION: | | | |
| • | | EPTINEZUMAB-JJMR (VYEPTI) IVPB in 100ml 0.9% normal saline, infuse over 30 minutes, iv. | | | |
| | | Use 0.2 or 0.22 micron in-line or add-on filter for administration. Do not shake. | | | |
| | - | must select one) | | | |
| Ţ | | 100 mg | | | |
| | | 300 mg | | | |
| FREC | UE | ENCY: (must select one) | | | |
| | | Every 12 weeks | | | |
| Ţ | | Other: | | | |
| AS N | EE | DED MEDICATIONS: | | | |
| • | | Sodium chloride 0.9% (NS) bolus 250 ml, Flush before and after IV medication(s) and as needed with NS. | | | |
| | | d included Nursing Orders: | | | |
| | | Notify provider if patient has signs/symptoms of infection or signs of active TB. | | | |
| • | | Remind patient to avoid live vaccines. | | | |
| • | | Vital signs: Monitor and record vital signs, tolerance, and presence of infusion-related reactions prior to | | | |
| | | infusion and at the end of infusion. | | | |
| • | | Insert peripheral IV if no iv access. | | | |
| • | | May use/access CVC line and give 500 units (5ml) heparin injection for central line care. | | | |
| • | | If hypersensitivity or infusion reactions develop, temporarily hold the infusion, and notify provider | | | |

Weight: _____kg Height: ____cm Allergies: _____Diagnosis Code: _____

HYPERSENSITIVITY INFUSION REACTION ORDERS

STOP infusion if:

MILD REACTION: Localized pruritus, rhinitis, localized rash, fever greater than 38 degrees C.

immediately. Include hypersensitivity reaction order set. (See attached form).

- 1. Stop infusion and maintain IV access with NS line.
- 2. Notify MD of symptoms and infusion reaction orders initiated.

MODERATE REACTION: Generalized pruritus, generalized flushing, rash, back pain, mild dyspnea, chills, hypotension with SBP less than 90 mmHg or greater than 20% decrease in SBP.

1. Stop infusion, but do not discard infusion bag/bottle unless instructed by MD that therapy is to be discontinued.



EPTINEZUMAB-JJMR (VYEPTI) Infusion

NAME:
BIRTHDATE:
INSURANCE:
PROVIDER NAME:
CLINIC NAME and Phone number:

Patient identification

- 2. Maintain IV access with NS line.
- 3. Place patients in a supine position with lower extremities elevated unless respiratory distress or nausea/vomiting.
- 4. Maintain airway.

SEVERE REACTION: Respiratory distress (bronchospasm, stridor, wheezing, persistent cough, respiratory depression, cardiac arrhythmia, chest pain, generalized urticaria (hives), syncope, gastrointestinal symptoms (abdominal pain, N/V, diarrhea), hypotension SBP less than 80 mmHg, face/throat/tongue swelling, shock, loss of consciousness.

- 1. Stop infusion, but do not discard bag/bottle unless instructed by MD that therapy is to be discontinued.
- 2. Stay with patient and have another nurse notify MD of symptoms and infusion reaction orders initiated.
- 3. Place patients in supine position with lower extremities elevated unless respiratory distress or nausea/vomiting.
- 4. Maintain airway.
- 5. Maintain IV access with NS line.
- 6. Inpatients: Activate code blue for loss of blood pressure, pulse, or consciousness.

MEDICATIONS:

- Acetaminophen (TYLENOL) tablet 650 mg, Oral, EVERY 4 HOURS PRN, Pain, Other, Mild reaction. Starting when released.
- DiphenhydrAMINE (Benadryl) injection, 25 mg, Intravenous, EVERY 15 MIN PRN, Moderate or severe reaction, may repeat x1. Starting when released, For 2 doses.
- Methylprednisolone sodium succinate (solu-MEDROL) 62.5mg/ml injection, 125 mg, Intravenous, ONCE PRN, Severe reaction. Starting when released, For 1 dose. Mix with 2 mL provided diluent to make 62.5 mg/mL.
- Famotidine (PEPCID) injection 20 mg, Intravenous, ONCE PRN, Moderate reaction, or anaphylaxis, starting when released. Dilute 2 mL of famotidine with 8 mL of normal saline to a final concentration of 2 mg/mL. Administer ordered dose over a period of at least 2 minutes.
- Albuterol 90 mcg/puff inhaler 2 puff, Inhalation, ONCE PRN, Severe reaction p. Starting when released, For 1 dose. Shake well. Use with spacer.
- Start oxygen. For MODERATE Reaction: Start 2 liters O2 per nasal cannula as needed for SpO2 less than 93%. For SEVERE Reaction: Start continuous pulse oximetry. Administer 6 to 8 liters per minute (LPM) via face mask, or up to 100% oxygen to maintain oxygen saturation greater than 90%.
- EPINEPHrine 1 mg/mL injection 0.3 mg. Intramuscular, EVERY 5 MIN PRN, Anaphylaxis. Starting when released, For 3 doses. Administer in the anterior lateral thigh using 1 1.5-inch needle for airway obstruction symptoms and/or hypotension.
- Sodium chloride 0.9% (NS) infusion 500ml. At 500 mL/hr., Intravenous, PRN, Moderate reaction, or anaphylaxis. Starting when released. Run wide open to gravity.



3/2023

EPTINEZUMAB-JJMR (VYEPTI) Infusion

NAME: INSURANCE: **PROVIDER NAME: CLINIC NAME and Phone number:**

Patient identification

| By signi | ing below, I | represent the followi | ing: | | | |
|-----------|---|--------------------------|--|--|--|--|
| | _ | = | nt (who is identified at the top of this form). | | | |
| I hold a | n active, uni | restricted license to pr | ractice medicine in Oregon. | | | |
| | | | | | | |
| My phy | sician licens | se Number is # | and I am acting within my scope of practice and | | | |
| authori | zed by law t | o order infusion of the | e medications and blood products described above for the patient | | | |
| identifie | ed on this fo | rm. | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| Date | | | | | | |
| Dloaco (| complete th | e following intake qu | actions | | | |
| | y status | le iollowing intake qu | estions. | | | |
| | Independe | ent | | | | |
| | □ Walker | | | | | |
| | □ Wheelchair | | | | | |
| _ | Fully depe | • | | | | |
| | c needs | | | | | |
| | Yes, briefly | / describe | | | | |
| | | | | | | |
| Transpo | ortation con | cerns | | | | |
| | Yes, briefly | / describe | | | | |
| | • | | | | | |
| Interpr | eter Service | required | | | | |
| | ☐ Yes, language | | | | | |
| | No | <u> </u> | | | | |
| | | | | | | |
| Outpati | ent Infusio | n Services Intake Tear | m: | | | |
| | | | e patient's preferred infusion center location: | | | |
| | | | | | | |
| | □ P(| ORTLAND | Phone- 503-215-6046 Fax- 503-487-3582 | | | |
| | □ W | /ILLAMETTE FALLS | Phone- 503-215-6046 Fax- 503-487-3582 | | | |
| | | IEDFORD | Phone- 541-732-7000 Fax- 541-732-3939 | | | |
| | □ H | OOD RIVER | | | | |
| | □ SI | EASIDE | Phone- 503-717-7650 Fax- 503-470-3146 | | | |
| | □ N | EWBERG | Phone- 503-537-6040 Fax- 503-205-8720 | | | |